Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm
- 1 September 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 6 (5), 988-997
- https://doi.org/10.1161/circheartfailure.113.000372
Abstract
Background—: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial found no difference in the primary outcome between warfarin and aspirin in 2305 patients with reduced left ventricular ejection fraction in sinus rhythm. However, it is unknown whether any subgroups benefit from warfarin or aspirin. Methods and Results—: We used a Cox model stepwise selection procedure to identify subgroups that may benefit from warfarin or aspirin on the WARCEF primary outcome. A secondary analysis added major hemorrhage to the outcome. The primary efficacy outcome was time to the first to occur of ischemic stroke, intracerebral hemorrhage, or death. Only age group was a significant treatment effect modifier ( P for interaction, 0.003). Younger patients benefited from warfarin over aspirin on the primary outcome (4.81 versus 6.76 events per 100 patient-years: hazard ratio, 0.63; 95% confidence interval, 0.48–0.84; P =0.001). In older patients, therapies did not differ (9.91 versus 9.01 events per 100 patient-years: hazard ratio, 1.09; 95% confidence interval, 0.88–1.35; P =0.44). With major hemorrhage added, in younger patients the event rate remained lower for warfarin than aspirin (5.41 versus 7.25 per 100 patient-years: hazard ratio, 0.68; 95% confidence interval, 0.52–0.89; P =0.005), but in older patients it became significantly higher for warfarin (11.80 versus 9.35 per 100 patient-years: hazard ratio, 1.25; 95% confidence interval, 1.02–1.53; P =0.03). Conclusions—: In patients <60 years, warfarin improved outcomes over aspirin with or without inclusion of major hemorrhage. In patients ≥60 years, there was no treatment difference, but the aspirin group had significantly better outcomes when major hemorrhage was included. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00041938.Keywords
This publication has 19 references indexed in Scilit:
- Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studiesEuropean Heart Journal, 2012
- Atrial fibrillation in heart failure patients: Prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registryEuropean Journal of Heart Failure, 2007
- The Seattle Heart Failure ModelCirculation, 2006
- Risks of Oral Anticoagulant Therapy With Increasing AgeArchives of Internal Medicine, 2005
- Heart failure with preserved left ventricular systolic functionJournal of the American College of Cardiology, 2004
- Oral anticoagulants in the elderlyBritish Journal of Haematology, 2003
- Warfarin, Aspirin, or Both after Myocardial InfarctionNew England Journal of Medicine, 2002
- Stroke in patients with heart failure and reduced left ventricular ejection fractionNeurology, 2000
- Incidence and Epidemiology of Heart FailureHeart Failure Reviews, 2000
- EditorialJournal of the American College of Cardiology, 1999